30 11, 2016

30 november, hoe nu verder!

2019-03-01T15:02:35+01:00

30 november, hoe nu verder! Vandaag,ben ik  na 3 maanden weer op bezoek geweest bij de hematoloog Niels van de Donk in het VU. En ik heb wat meer duidelijkheid gekregen voor mijzelf, al is het afwachten wat er uiteindelijk gaat gebeuren. Mijn lichte ketens (max. 27 lamda ) zijn binnen 3 maanden gestegen van 537  naar 770, dus ruim te veel. En reden om een behandeling te starten. Ik zat tot nu toe nog in

30 november, hoe nu verder!2019-03-01T15:02:35+01:00
23 11, 2016

Progress and Paradigms in Multiple Myeloma (p53 effects)

2019-01-29T13:16:59+01:00

Progress and Paradigms in Multiple Myeloma Kenneth C. Anderson DOI: 10.1158/1078-0432.CCR-16-0625 Published 15 November 2016 Article Figures & Data Info & Metrics PDF Abstract Remarkable progress has been achieved in multiple myeloma, and patient median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment paradigm and patient outcome have been transformed. The definition of patients

Progress and Paradigms in Multiple Myeloma (p53 effects)2019-01-29T13:16:59+01:00
22 11, 2016

Skip the Bone Marrow Biopsy, Single Cell Blood Analysis for Myeloma is Coming Soon

2019-01-29T13:16:59+01:00

BY PAUL KLEUTGHEN Sorce : http://www.myelomacrowd.org/stem-cell-transplant-and-the-tp53-deletion-in-multiple-myeloma-patients/ Hate myeloma bone marrow biopsies? You’re not alone. Soon, the happy day may come where we don’t need them. A new article in the journal Science Translational Medicine describes a new testing method where single cells of peripheral blood can be analyzed for a myeloma diagnosis and genetic subtyping without the need to do a bone marrow biopsy. For myeloma patients, this is a significant breakthrough that makes initial diagnosis, monitoring

Skip the Bone Marrow Biopsy, Single Cell Blood Analysis for Myeloma is Coming Soon2019-01-29T13:16:59+01:00
Ga naar de bovenkant